From bench to bedside, a diverse portfolio of investigational compounds across different stages of drug development

ITCI pipeline is focused on three platforms: The ITI-007 platform, of which lumateperone is the most advanced program; the PDE platform, of which ITI-214, a PDE1 inhibitor, is the most advanced program; and our discovery platform, which includes ITI-333.